National Bank of Canada FI Has $16.23 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

National Bank of Canada FI raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 214,861 shares of the medical research company’s stock after purchasing an additional 9,352 shares during the quarter. National Bank of Canada FI’s holdings in Edwards Lifesciences were worth $16,234,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. AustralianSuper Pty Ltd acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $168,519,000. Nordea Investment Management AB grew its position in shares of Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after buying an additional 1,488,791 shares during the period. Wellington Management Group LLP increased its stake in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares in the last quarter. FMR LLC increased its stake in shares of Edwards Lifesciences by 61.1% in the 3rd quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock valued at $215,557,000 after acquiring an additional 1,179,637 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $60,971,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Mizuho raised their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Oppenheimer boosted their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Piper Sandler increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Finally, Morgan Stanley increased their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.27.

Insider Buying and Selling at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian acquired 580 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Bernard J. Zovighian bought 580 shares of the business’s stock in a transaction on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the sale, the director now directly owns 4,486 shares in the company, valued at approximately $380,278.22. The disclosure for this sale can be found here. Insiders sold 237,749 shares of company stock worth $20,920,934 in the last quarter. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.9 %

Shares of EW stock opened at $85.85 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The company has a market capitalization of $51.73 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a 50-day simple moving average of $90.05 and a two-hundred day simple moving average of $79.69.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.